Schizophrenia is a poorly served market. Most existing treatments work by blocking the action of the neurotransmitter dopamine, but these drugs fail to address some symptoms of the disease while causing serious side effects.

Researchers at Yale University School of Medicine (West Haven, Conn.) last week published work in Science focused on another neurotransmitter, glutamate. They reported that lowering brain levels of